Advertisement


Kieron M. Dunleavy, MD, on B-Cell Malignancies: Novel-Novel Drug Combinations

Pan Pacific Lymphoma Conference 2018

Advertisement

Kieron M. Dunleavy, MD, of George Washington University, discusses the need for drug combinations to improve lymphoma therapy, despite unexpected toxicities, as our understanding of the molecular biology grows.



Related Videos

Lymphoma

Andrew D. Zelenetz, MD, PhD, on NHL: Clinical Applications of Genomic Studies

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the various ways genomics can be used in diagnosing and treating non-Hodgkin lymphoma and the need...

Lymphoma
Immunotherapy

Julie M. Vose, MD, MBA, and David G. Maloney, MD, PhD, on NHL: Update on CAR T-Cell Therapies

Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, and David G. Maloney, MD, PhD, of Fred Hutchinson Cancer Research Center and winner of this y...

Lymphoma

Steven M. Horwitz, MD, on CD 30+ PTCL Subtypes: Treatment Update

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses aggressive subtypes of peripheral T-cell lymphoma and the coming data that may help clarify what c...

Lymphoma

Laurie H. Sehn, MD, MPH, on HGBCL With Comorbidities: Upfront Therapies

Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Centre for Lymphoid Cancer, discusses the challenges of treating high-grade B-cell lymphoma in older patients and thos...

Lymphoma
Immunotherapy

Stephen M. Ansell, MD, PhD, on Hodgkin Lymphoma: Beyond Checkpoint Inhibitors

Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses the efficacy of PD-1 blockade in Hodgkin lymphoma, new findings related to PD-1 therapy, current combination approac...

Advertisement

Advertisement



;
Advertisement